Add Company
Join Now

Mercy BioAnalytics Home Revenue and Competitors

License our Company Data API

Natick, MA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Mercy BioAnalytics Home's estimated annual revenue is currently $7.4M per year.(i)
  • Mercy BioAnalytics Home's estimated revenue per employee is $155,000

Employee Data

  • Mercy BioAnalytics Home has 48 Employees.(i)
  • Mercy BioAnalytics Home grew their employee count by 30% last year.

Mercy BioAnalytics Home's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
VP Program and Portfolio ManagementReveal Email/Phone
3
SVPReveal Email/Phone
4
VP Quality, Regulatory, and Clinical AffairsReveal Email/Phone
5
VP Clinical AffairsReveal Email/Phone
6
VP, Marketing and Strategic AlliancesReveal Email/Phone
7
Director, Antibody DevelopmentReveal Email/Phone
8
Director ResearchReveal Email/Phone
9
Director Assay DevelopmentReveal Email/Phone
10
Chief Financial OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Mercy BioAnalytics Home?

Mercy BioAnalytics is on a mission to improve and save the lives of people across the globe through the early detection of cancer, when it is most curable. We've developed a process which uses nano-particles that are extraordinarily abundant in blood and carry information about their parent cell – known as extracellular vesicles, or EVs – to detect stage I cancer. We are seeking dedicated and passionate individuals to join us in realizing this vision.

keywords:N/A

N/A

Total Funding

48

Number of Employees

$7.4M

Revenue (est)

30%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.7M487%N/A
#2
$12.6M528%N/A
#3
$4.7M526%N/A
#4
$17.5M554%N/A
#5
$8.5M576%N/A